Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

The zymogenic form of SARS-CoV-2 main protease: A discrete target for drug discovery

P. Novotný, J. Humpolíčková, V. Nováková, S. Stanchev, K. Stříšovský, M. Zgarbová, J. Weber, R. Kryštůfek, J. Starková, M. Hradilek, A. Moravcová, J. Günterová, K. Bach, P. Majer, J. Konvalinka, T. Majerová

. 2025 ; 301 (1) : 108079. [pub] 20241214

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc25010440

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) main protease (Mpro) autocatalytically releases itself out of the viral polyprotein to form a fully active mature dimer in a manner that is not fully understood. Here, we introduce several tools to help elucidate differences between cis (intramolecular) and trans (intermolecular) proteolytic processing and to evaluate inhibition of precursor Mpro. We found that many mutations at the P1 position of the N-terminal autoprocessing site do not block cis autoprocessing but do inhibit trans processing. Notably, substituting the WT glutamine at the P1 position with isoleucine retains Mpro in an unprocessed precursor form that can be purified and further studied. We also developed a cell-based reporter assay suitable for compound library screening and evaluation in HEK293T cells. This assay can detect both overall Mpro inhibition and the fraction of uncleaved precursor form of Mpro through separable fluorescent signals. We observed that inhibitory compounds preferentially block mature Mpro. Bofutrelvir and a novel compound designed in-house showed the lowest selectivity between precursor and mature Mpro, indicating that inhibition of both forms may be possible. Additionally, we observed positive modulation of precursor activity at low concentrations of inhibitors. Our findings help expand understanding of the SARS-CoV-2 viral life cycle and may facilitate development of strategies to target precursor form of Mpro for inhibition or premature activation of Mpro.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25010440
003      
CZ-PrNML
005      
20250429134649.0
007      
ta
008      
250415s2025 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.jbc.2024.108079 $2 doi
035    __
$a (PubMed)39675720
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Novotný, Pavel $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Prague, Czech Republic; Faculty of Science, Department of Physical and Macromolecular Chemistry, Charles University in Prague, Prague, Czech Republic
245    14
$a The zymogenic form of SARS-CoV-2 main protease: A discrete target for drug discovery / $c P. Novotný, J. Humpolíčková, V. Nováková, S. Stanchev, K. Stříšovský, M. Zgarbová, J. Weber, R. Kryštůfek, J. Starková, M. Hradilek, A. Moravcová, J. Günterová, K. Bach, P. Majer, J. Konvalinka, T. Majerová
520    9_
$a Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) main protease (Mpro) autocatalytically releases itself out of the viral polyprotein to form a fully active mature dimer in a manner that is not fully understood. Here, we introduce several tools to help elucidate differences between cis (intramolecular) and trans (intermolecular) proteolytic processing and to evaluate inhibition of precursor Mpro. We found that many mutations at the P1 position of the N-terminal autoprocessing site do not block cis autoprocessing but do inhibit trans processing. Notably, substituting the WT glutamine at the P1 position with isoleucine retains Mpro in an unprocessed precursor form that can be purified and further studied. We also developed a cell-based reporter assay suitable for compound library screening and evaluation in HEK293T cells. This assay can detect both overall Mpro inhibition and the fraction of uncleaved precursor form of Mpro through separable fluorescent signals. We observed that inhibitory compounds preferentially block mature Mpro. Bofutrelvir and a novel compound designed in-house showed the lowest selectivity between precursor and mature Mpro, indicating that inhibition of both forms may be possible. Additionally, we observed positive modulation of precursor activity at low concentrations of inhibitors. Our findings help expand understanding of the SARS-CoV-2 viral life cycle and may facilitate development of strategies to target precursor form of Mpro for inhibition or premature activation of Mpro.
650    _2
$a lidé $7 D006801
650    12
$a SARS-CoV-2 $x enzymologie $x účinky léků $x metabolismus $x genetika $7 D000086402
650    _2
$a HEK293 buňky $7 D057809
650    12
$a objevování léků $x metody $7 D055808
650    12
$a koronavirové proteasy 3C $x metabolismus $x antagonisté a inhibitory $x chemie $x genetika $7 D000086782
650    12
$a antivirové látky $x farmakologie $x chemie $7 D000998
650    _2
$a inhibitory proteas $x farmakologie $x chemie $7 D011480
650    _2
$a farmakoterapie COVID-19 $7 D000093485
650    _2
$a mutace $7 D009154
650    _2
$a proteolýza $7 D059748
655    _2
$a časopisecké články $7 D016428
700    1_
$a Humpolíčková, Jana $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Prague, Czech Republic
700    1_
$a Nováková, Veronika $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Prague, Czech Republic; Faculty of Science, Department of Genetics and Microbiology, Charles University in Prague, Prague, Czech Republic
700    1_
$a Stanchev, Stancho $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Prague, Czech Republic
700    1_
$a Stříšovský, Kvido $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Prague, Czech Republic
700    1_
$a Zgarbová, Michala $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Prague, Czech Republic; Faculty of Science, Department of Genetics and Microbiology, Charles University in Prague, Prague, Czech Republic
700    1_
$a Weber, Jan $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Prague, Czech Republic
700    1_
$a Kryštůfek, Robin $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Prague, Czech Republic; Faculty of Science, Department of Physical and Macromolecular Chemistry, Charles University in Prague, Prague, Czech Republic
700    1_
$a Starková, Jana $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Prague, Czech Republic
700    1_
$a Hradilek, Martin $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Prague, Czech Republic
700    1_
$a Moravcová, Adéla $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Prague, Czech Republic; Department of Biochemistry and Microbiology, University of Chemistry and Technology Prague, Prague, Czech Republic
700    1_
$a Günterová, Jana $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Prague, Czech Republic
700    1_
$a Bach, Kathrin $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Prague, Czech Republic; Faculty of Science, Department of Genetics and Microbiology, Charles University in Prague, Prague, Czech Republic
700    1_
$a Majer, Pavel $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Prague, Czech Republic
700    1_
$a Konvalinka, Jan $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Prague, Czech Republic; Faculty of Science, Department of Biochemistry, Charles University in Prague, Prague, Czech Republic
700    1_
$a Majerová, Taťána $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Prague, Czech Republic. Electronic address: tatana.majerova@uochb.cas.cz
773    0_
$w MED00002546 $t The Journal of biological chemistry $x 1083-351X $g Roč. 301, č. 1 (2025), s. 108079
856    41
$u https://pubmed.ncbi.nlm.nih.gov/39675720 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250415 $b ABA008
991    __
$a 20250429134645 $b ABA008
999    __
$a ok $b bmc $g 2311661 $s 1247521
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2025 $b 301 $c 1 $d 108079 $e 20241214 $i 1083-351X $m The Journal of biological chemistry $n J Biol Chem $x MED00002546
LZP    __
$a Pubmed-20250415
Zpět

Najít záznam

Citační ukazatele

Možnosti archivace